MX2021014102A - Terapia de vacuna anti-abeta. - Google Patents
Terapia de vacuna anti-abeta.Info
- Publication number
- MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A MX 2021014102 A MX2021014102 A MX 2021014102A
- Authority
- MX
- Mexico
- Prior art keywords
- administered
- mpla
- amyloid
- amount
- vaccine therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014102A true MX2021014102A (es) | 2022-02-11 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014102A MX2021014102A (es) | 2019-05-21 | 2020-05-20 | Terapia de vacuna anti-abeta. |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI916375B (zh) * | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
| WO2025109524A1 (en) * | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| MX2011009654A (es) * | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
-
2020
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en not_active Ceased
- 2020-05-20 MY MYPI2021006840A patent/MY210394A/en unknown
- 2020-05-20 JP JP2021569155A patent/JP7701734B2/ja active Active
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 IL IL288252A patent/IL288252B1/en unknown
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL288252A (en) | 2022-01-01 |
| JP2022533422A (ja) | 2022-07-22 |
| MY210394A (en) | 2025-09-18 |
| KR20220010552A (ko) | 2022-01-25 |
| CN113853214A (zh) | 2021-12-28 |
| CA3138145A1 (en) | 2020-11-26 |
| SG11202112329RA (en) | 2021-12-30 |
| JP7701734B2 (ja) | 2025-07-02 |
| IL288252B1 (en) | 2026-06-01 |
| TW202110425A (zh) | 2021-03-16 |
| US20220226447A1 (en) | 2022-07-21 |
| WO2020234405A1 (en) | 2020-11-26 |
| BR112021023209A2 (pt) | 2022-01-18 |
| EP3972633A1 (en) | 2022-03-30 |
| CL2021003051A1 (es) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY210394A (en) | Anti-abeta vaccine therapy | |
| Barr et al. | ISCOMs (immunostimulating complexes): the first decade | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| CA2181832A1 (en) | Immunization by inoculation of dna transcription unit | |
| AU2012257771C1 (en) | Vaccine against Streptococcus pneumoniae | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| US20050002951A1 (en) | Novel method of inducing antigen-specific t cells | |
| MY206596A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| PH12021552683A1 (en) | Heterologous administration of tau vaccines | |
| WO2005000348A2 (en) | Vaccines inducing nkt-cell and toll-like-receptor activation | |
| JP2017511327A5 (cg-RX-API-DMAC7.html) | ||
| JP2021521149A5 (cg-RX-API-DMAC7.html) | ||
| RU2018120009A (ru) | Способ вакцинации против аутоантигена у пациента-человека | |
| DK2491946T3 (en) | Adjuvant for vaccines | |
| JP2010514669A5 (cg-RX-API-DMAC7.html) | ||
| US20230285531A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| AU2003212170A1 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| WO2017070735A1 (en) | Liposomal vaccine | |
| MX2025008675A (es) | Terapia con vacuna anti-abeta | |
| EA202193183A1 (ru) | Терапия с помощью вакцины против бета-амилоида | |
| WO2001078774A3 (en) | Recombinant intracellular pathogen vaccines and methods for use | |
| FR2248025A2 (en) | Vaccine compsns. - contg. N-acyl muramic acid deriv. as adjuvant | |
| FR2324311A1 (fr) | Adjuvants immunologiques solubles dans l'eau, notamment pour vaccins, obtenus a partir de mycobacteries et autres micro-organismes |